Although dual antiplatelet therapy using cilostazol is associated with a lower risk of recurrent stroke in men, it has no significant benefit for women, a sub-analysis of CSPS.com results suggests.

Cilostazol may thus be particularly useful for treatment of patients with sick sinus syndrome associated with disorders that require antithromboembolic therapy.

Cilostazol given prior to a surgical procedure resulted in a safer transition off dual antiplatelet therapy (DAPT) by reducing the risk the risk of bleeding during the operation in patients with a ...

While cilostazol has never been studied in this setting, there is at least some biologic plausibility for its use in this scenario.

In patients with femoropopliteal lesions, additional treatment with cilostazol after implantation of a drug-eluting stent is associated with significantly lower restenosis rates at 1 year ...

Cilostazol and isosorbide mononitrate, two widely available drugs that have beneficial effects on endothelial function, appear to improve functional and cognitive outcomes when used in patients who ...

CILON-T Published: Cilostazol Reduces Platelet Reactivity, Not Events Triple antiplatelet therapy consisting of cilostazol added to clopidogrel and aspirin does not improve clinical outcomes in ...

The antiplatelet drug cilostazol (which prevents the blood from clotting) works as well as, and might be better than, aspirin in helping to prevent a secondary stroke in Asian patients, but with ...

Cilostazol tablets are the AB-rated generic equivalent of Otsuka America Pharmaceutical's Pletal tablets. Teva said the shipment of Cilostazol is expected to begin immediately.

The long-term combination of cilostazol with aspirin or clopidogrel resulted in fewer recurrent strokes than with aspirin or clopidogrel alone in high-risk patients.

For patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), adjunctive loading dose of cilostazol is not associated with prevention of periprocedural ...

Cilostazol inhibited insulin-induced and LXR-agonist-induced expression of SREBP-1c and its downstream targets, acetyl-CoA carboxylase and fatty acid synthase, in cultured hepatocytes.